“Updates in Nephrology” & “Myelodysplastic Syndromes / Neoplasms (MDS): a CHip off the old block” (Hybrid Event)

Jair Munoz Mendoza, MD
University of Miami Miller School of Medicine

Dr. Munoz Mendoza received his medical degree from the Universidad Nacional Mayor de San Marcos in Lima, Peru. He completed internal medicine residency at Albert Einstein Medical Center in Philadelphia, and fellowship in Nephrology at Stanford University in Palo Alto, California. After finishing fellowship, he joined the faculty at the University of Miami, Katz Family Division of Nephrology and Hypertension in 2011.  Dr. Munoz Mendoza is currently an Associate Professor of Clinical Medicine. He is the medical director of DaVita Miami Campus, our main outpatient dialysis unit, and has a research interest in the relationships between the non-neoplastic histopathological features and kidney function in patients undergoing nephrectomy and cardiovascular disease in patients with chronic kidney disease.

Sangeetha Venugopal, MD
Assistant Professor of Clinical 
University of Miami Miller School of Medicine 

Dr. Venugopal completed her medical education in India followed by internal medicine residency at the Montefiore Medical Center New York and Hematology Oncology Fellowship at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, New York. Additionally, she did an advanced Leukemia Fellowship at the MD Anderson Cancer Center, Houston Texas and a Masters in clinical research at the GWU, Washington DC. She is keenly interested in myeloid malignancy clinical research and in particular early phase clinical development of novel and rationally targeted therapies.

_______________________________________________________________________________________________________________________________________________________________________________________________

Join Meeting!

Dr. Munoz Mendoza’s OBJECTIVES:

• Explain the effects of SGL2i on patients with CKD: EMPA-Kidney Study
• Examine the role of GLP1-ra in patients with diabetic kidney disease
• Analyze the role of thiazides on the management of hypertension in advanced CKD: CLICK study

Dr. Venugopal’s OBJECTIVES:

• Analyze the evolution of clonal cytopenia of undetermined significance (CCUS) to MDS
• Classify MDS into appropriate prognostic subgroups for risk adapted therapy
• Determine the most appropriate treatment strategy based on risk stratification

FACULTY DISCLOSURES:

Dr. Munoz Mendoza has indicated that he has no relevant financial relationships with commercial interests.
Dr. Venugopal has indicated that she has no relevant financial relationships with commercial interests

PLANNING COMMITTEE DISCLOSURE:

Dr. Deshpande has indicated that he has no relevant financial relationships with commercial interests.
Dr. Weiss has indicated the following relevant financial relationships with commercial interests:

Financial Relationship                                     Commercial Interest/Organization
Consultant/Contractor                                       Prizm LLC

All the relevant financial relationships for these individuals have been mitigated.

TARGET AUDIENCE:
Primary care physicians.

ACCREDITATION:
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.